Mechanistic insight into the attenuation of initial pilocarpine-induced seizures in young rats by a non-convulsive MSO dose

Marek J. Pawlik 1,* ORCID ID: 0000-0002-9060-7230, Blanca I. Aldana 2 ORCID ID: 0000-0002-5027-1218, Lautaro F. Belfiori-Carrasco 2 ORCID ID: 0000-0003-1930-1332, Marta Obara-Michlewska 1 ORCID ID: 0000-0003-3659-1335, Mariusz P. Popek 1 ORCID ID: 0000-0003-4394-3394, Anna Maria Czarnecka 1 ORCID ID: 0000-0003-4235-2963, Jan Albrecht 1,* ORCID ID: 0000-0001-6063-6228

1 Department of Neurotoxicology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland; mobara@imdik.pan.pl (M.O.-M.); mpopek@imdik.pan.pl (M.P.P.); aczarnecka@imdik.pan.pl (A.M.C.)
2 Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; blanca.aldana@sund.ku.dk (B.I.A); vch443@ku.dk (L.F.B.-C.)
* Correspondence: jalbrecht@imdik.pan.pl (J.A); mpawlik@imdik.pan.pl (M.J.P.);
Tel.: +48-22-6086-617 (J.A.); +48-22-6086-441 (M.J.P.)

Abstract: Pretreatment with non-convulsive dose of methionine sulfoximine (MSO) attenuated lithium-pilocarpine-induced (Li-Pilo) seizures in young rats [1]. We hypothesized that the effect of MSO results from a) glutamine synthetase block-mediated inhibition of conversion of Glu/Gln precursors to neurotransmitter Glu, and/or from b) altered synaptic Glu release. Pilo was administered 60 min prior to sacrifice, MSO at 75 mg/kg, i.p., 2.5 h earlier. [1,2-13C]acetate and [U-13C]glucose were i.p.-injected either together with Pilo (onset) or 15 min before sacrifice (final phase). Their conversion to Glu and Gln in hippocampus and entorhinal cortex was followed using [13C] gas chromatography-mass spectrometry. Release of in vitro loaded [1H]d-Asp from ex vivo brain slices was measured in continuously collected superfusates. Protein and mRNA expression were measured by Western Blot and real-time PCR techniques, respectively. At no time point nor brain region did MSO modify incorporation of [13C] to Glu or Gln in Pilo-treated rats. MSO pretreatment decreased by ~37% high potassium-induced [1H]d-Asp release and reduced by ~50% the synaptic vesicular Glu transporter VGLUT1 protein, but not mRNA content in the hippocampus. The results indicate that MSO at non-convulsive dose mitigates the initial Pilo-induced seizures by interfering with synaptic Glu-release but not with neurotransmitter Glu recycling.

Keywords: epilepsy; glutamatergic transmission; glutamine synthesis; methionine sulfoximine; metabolomics

1. Introduction

In mammalian brain, glutamine synthetase (GS) is bimodally involved in the regulation of excitatory, glutamatergic transmission [2,3]. On one hand, GS-mediated conversion of Glu and ammonia to Gln in astrocytes neutralizes Glu newly released from neurons. On the other hand, a portion of Gln newly formed in astrocytes is transferred back to neurons by specific Gln transporters catalyzing its astrocytic release (system N) and neuronal uptake (system A), respectively [4–6]. Here it enriches neurotransmitter pool of Glu: the above sequence of events are defined as the glutamine-glutamate cycle (GGC).

Methionine sulfoximine (MSO) is an irreversible GS inhibitor [7]. Instant GS inhibition by high MSO doses rapidly stimulates glutamatergic transmission, inducing convulsions and seizures [7–9], while GS inactivation associated with prolonged MSO treatment is accompanied by hippocampal sclerosis and spontaneous recurrent seizures (SRS) resulting from inefficient Glu uptake, a status manifesting chronic temporal lobe epilepsy (TLE) [8,10–12]. GS loss in brain-vulnerable regions (mainly hippocampus) has also been
found to correlate with advanced TLE induced by other chemical stimuli, including pilocarpine (Pilo) [13–15] or kainic acid (KA) [16].

On the other hand, exogenously added Gln will induce a long-lasting, glutamatergic transmission-bolstering effect. This has been directly demonstrated in striatal cortical slices [17], but has also been recorded in epilepsy models: in entorhinal cortical slices derived from Pilo-treated chronic epileptic rats [18], in rats with KA-induced seizures [19], and in an in vitro model of post-traumatic epilepsy [20]. The role of Gln in promoting excitatory transmission and seizures has also been demonstrated in experiments employing low MSO doses causing moderate inhibition of GS. Low MSO depressed glutamatergic transmission and epileptiform discharges in cerebral cortical slices in vitro [21,22]. In vivo, intracerebral administration of MSO reduced amygdala kindling-induced seizures [23].

We recently have demonstrated that in 24-day rats treated with lithium-pilocarpine (Li-Pilo), pretreatment with MSO at a low dose which produced no convulsions, delayed the onset of, and attenuated the initial convulsive and electrographic seizures [1]. It appeared reasonable to speculate that MSO at this low dose inhibited an aspect of glutamatergic transmission critical for provoking the initial seizures. In this study we tested two not mutually exclusive hypotheses regarding the mechanism by which MSO could induce the inhibition. The first was that, MSO interferes with the GGC in a way affecting de novo Glu synthesis in this model. To test this hypothesis, $^{13}$C mass spectrometry was employed to follow incorporation in vivo of $^{13}$C labelled metabolic precursors: acetate and glucose, to Glu and Gln. This procedure has previously been used to study Glu synthesis and metabolism in models of brain pathologies associated with enhanced glutamatergic transmission [24–30], including treatments with convulsive MSO dose in vivo [24] and in vitro [30–32]. The main labelling patterns of the metabolites from $[^{13}\text{C}]$glucose or $[1,2-^{13}\text{C}]$acetate in the experimental setting of the present investigation are detailed in Scheme 1.

**Scheme 1.** Schematic representation of the main labelling patterns obtained after incubation with $[^{13}\text{C}]$glucose or $[1,2-^{13}\text{C}]$acetate. $[^{13}\text{C}]$glucose is taken up by cells in the brain tissue and metabolized to $[^{13}\text{C}]$pyruvate (M+3) during glycolysis. $[^{13}\text{C}]$pyruvate which in turn can be metabolized in the tricarboxylic acid (TCA) cycle, entering as $[1,2-^{13}\text{C}]$Acetyl-Coenzyme A ($[1,2-^{13}\text{C}]$Ac-CoA) which reacts with unlabelled oxaloacetate and, hence, double-labelled (M+2) TCA cycle intermediates are produced, illustrated as blue circles. $[1,2-^{13}\text{C}]$acetate can also enter the TCA cycle via $[1,2-^{13}\text{C}]$Ac-CoA and generate double-labelled intermediates. The labelled neuroactive amino acid $[4,5-^{13}\text{C}]$glutamate (M+2) can be
formed from α[4,5-13C]ketoglutarate (α-kg M+2). From glutamate (M+2), [4,5-13C]glutamine (M+2) can be synthesized in the astrocytes by glutamine synthase (GS). In the second turn of the TCA cycle, [1,2-13C]Ac-CoA reacts with oxaloacetate M+2 formed in the first turn of the cycle, resulting in the production of M+3 and M+4 labelled metabolites (depicted with grey circles).

The second hypothesis was that MSO interferes with the availability of Glu at the synapse by modifying its release and/or reuptake. Here we took into consideration earlier published data demonstrating that MSO affects Glu transport in various brain preparations in vivo [33] and in vitro [34,35]. To account for this hypothesis, we tested the effect of MSO on the uptake and release of the newly taken up 3H-labelled Glu surrogate, D-aspartate ([3H]D-Asp) in ex vivo brain slices derived from rats treated with a low dose of MSO. High, depolarizing potassium concentrations were used as a generic release stimulus. Having found that MSO in the present setting inhibits [3H]D-Asp release, we begun a search into the mechanism by which MSO interferes with the mechanism of Glu release. Towards this end we measured the expression of VGLUT1, the principal vesicular Glu transporter responsible for loading synaptic vesicles with glutamate [36].

2. Results
2.1. Generation of Glu and Gln from [U-13C]glucose or [1,2-13C]acetate
2.1.1. Glutamate
At 15 minutes after Pilo administration 13C-enrichment of Glu from labelled glucose was drastically decreased by MSO both after the first (M+2) and the second turnover (M+4) (Figure 1. A.). In the latter, the levels of 5 out of 6 samples were below the detection limit of GC-MS. However, Pilo treatment alone did not induce changes in the enrichment (Pilo group), MSO failed to decrease the 13C-enrichment from glucose in Pilo-treated rats (MSO+Pilo group). No changes after either combination of treatments were apparent in the entorhinal cortex, except for a statistically insignificant tendency towards increase of M+4 labeling in Glu (Figure 1. C.). A slight tendency to decrease of Glu labelling from acetate by MSO became apparent in the entorhinal cortex (Figure 1. D.) but not in the hippocampus (Figure 1. B.). Again, MSO failed to decrease the 13C-enrichment from acetate, leaving M+2 and M+4 Glu levels unchanged relative to the control in both brain structures. No noteworthy changes in Glu 13C enrichment were observed at 60 min after Pilo administration (Figure 1. E.-H.). In both time points and brain structures, and under either condition, 13C-enrichment in Glu derived from labeled glucose was around two times higher than that derived from acetate.
Figure 1. Percentage of $^{13}$C-enrichment in glutamate derived from [U-$^{13}$C]glucose or [1,2-$^{13}$C]acetate in hippocampus and entorhinal cortex of TLE model rats. * - p < 0.05, one-way ANOVA with Tukey’s correction; Control, MSO, Pilo, MSO+Pilo N = 6; mean ± SEM. Designations “15” and “60” refer to the onset and final phase of Pilo action and correspond to 150-165 min or 195-210 min time of action of MSO, respectively, rendering in each case a 15 min presence of the isotope in the body.

2.1.2. Glutamine

Similarly to glutamate, glutamine enrichment from $^{13}$C-labelled glucose in hippocampus at 15 minutes was significantly reduced by MSO after the first turnover and almost indeterminable after the second turnover (4 out of 6 samples below detection limit) (Figure 2. A.). At 15 min, MSO failed to significantly affect glutamine enrichment from glucose in the entorhinal cortex (Figure 2. C.). A slight tendency towards decrease of Gln labelling
by MSO was observed in both structures at 60 minutes when glucose was used as a precursor (Figure 2. E, G.). At 15 min, a tendency of MSO to decrease Gln labelling was also observed in acetate-derived metabolites in both structures; however, the effect did not reach statistical significance in either of the groups (Fig. 2. B, D.). No change was observed in either structure after either treatment at 60 min (Fig. 2. F, H.). Unlike Glu, where majority of the newly labelled neurotransmitter originated from glucose, more than twice as much Gln was labelled from acetate than from glucose.

**Figure 2.** Percentage of $^{13}$C-enrichment in glutamine derived from [U-$^{13}$C]glucose or [1,2-$^{13}$C]acetate in hippocampus and entorhinal cortex of TLE model rats. * - p < 0.05, one-way ANOVA with Tukey’s correction; Control, MSO, Pilo,
MSO+Pilo N = 6; mean ± SEM. Designations “15’” and “60’” refer to the onset and final phase of Pilo action and correspond to 150-165 min or 195-210 min time of action of MSO, respectively, rendering in each case a 15 min presence of the isotope in the body.

2.2 Glu and Gln brain tissue content in MSO and/or Pilo-treated rats (HPLC study)

None of the treatments produced statistically significant changes in hippocampal or entorhinal cortical Glu at either time point. Considering all the experimental variants, the Glu content ranged from 531.1 ± 89.4 in entorhinal cortex to 788.1 ± 187.8 in hippocampus (nmol/mg of protein, mean ± SD). This result is not surprising, as changes in rat brain Glu content have been reported to be refractory to a 6 h treatment with MSO doses 2 times higher than those used in the present study [37].

2.3. [3H]D-Asp efflux

D-Asp release evoked by K⁺-induced depolarization was markedly lowered due to administration of MSO (Figure A.). For four consecutive minutes after potassium pulse [3H]D-Asp levels in individual fractions were found to be significantly decreased in comparison with control. Area under the curve was on average 37% smaller in the MSO group as well (2.445 ± 0.139 vs. 3.888 ± 0.239 in control), indicating that the whole released pool of D-Asp was reduced. Baseline level of D-Asp was slightly decreased (0.204 ± 0.006 % in MSO vs. 0.309 ± 0.005 % in control) which may suggest that D-Asp transport is affected by MSO in normal conditions as well, however, these changes were statistically insignificant.

2.4. [3H]D-Asp uptake

There was no change in kinetics of [3H]D-Asp uptake, especially at lower concentrations of D-Asp (50 – 500 μM) (Fig. 3. B.). At higher concentrations (1000-2000 μM) a slight decrease of the uptake rate was observed in the MSO-treated group, however, the impact of MSO was not pronounced enough to significantly change Vₘₐₓ or Kₘᵢₙ parameters. This
lack of effect of MSO confirms an earlier observation of unchanged Glu uptake in MSO-pretreated rat brain synaptosomes [34].

2.5. VGlUT1 expression

The level of VGLUT1 protein in the hippocampus, 3.5 hours after MSO administration, was significantly decreased to 47.17 % of the control (Figure 4). VGLUT1 mRNA expression was not altered by MSO treatment (Figure 4).

![VGLUT1 expression](image)

Figure 4. VGLUT1 mRNA and protein content with representative electrophorograms in the hippocampus of rats that received or not (control) MSO 3.5 h before decapitation. ** - p < 0.01, t-test; mRNA: control, MSO N = 6; protein: control N = 5, MSO N = 6; mean ± SEM.

3. Discussion

Our primary hypothesis regarding the mechanism by which low dose MSO attenuates the initial seizures in the Li-Pilo model was that MSO decreases the synthesis of neurotransmitter Glu by reducing the formation of its precursor Gln. The hypothesis was verified by measuring the effects of MSO treatment on the incorporation in vivo of 13C labelled metabolic precursors: acetate and glucose to neurotransmitter Glu and Gln in hippocampus and entorhinal cortex, the two structures involved in the propagation of pilocarpine-induced seizures [38]. The only statistically significant change observed throughout the study was a decrease of 13C-enrichment of both Glu and Gln from glucose in hippocampus in the period of 150-165 min after MSO administration alone. However, at the very same time point, MSO failed to modulate in either direction the enrichment from glucose in rats with Li-Pilo-evoked seizures. Otherwise, MSO did not induce any significant effect on 13C-enrichment from glucose nor acetate, in any animal group either at the onset (15 min) or at final stage (60 min) of the development of initial seizures. It is intriguing that the decrease by MSO of 13C-enrichment from glucose at 15 min was not observed at the later time point. Tentatively, this may be due to the biphasic effect of MSO on GS activity, leaving open the time brackets of the system in the final phase. A study with human GS revealed that initial competitive inhibition is a reversible process and is followed by irreversible activation [39]. The general absence of the effects of extrinsic factors became apparent notwithstanding the predictable metabolic fates of 13C glucose or 13C acetate in this experimental setting. Both preferential 13C-enrichment of Glu from glucose and of Gln from acetate are a good fit into the present views on the role of either of the compound as a metabolic precursor in neurons and astrocytes. Indeed, neurotransmitter pool of Glu is thought to be preferentially synthesized from glucose. The de novo synthesis may occur
directly in neurons [40], or in astrocytes. The synthesis in astrocytes depends on anaplerosis, i.e. reactions providing a net increase in TCA cycle intermediates [41]. The primary anaplerotic enzyme in the brain, pyruvate carboxylase (PC), which serves as the main pathway of de novo glutamate synthesis is exclusively expressed in astrocytes [42,43]; reviewed by Schousboe et al. [44]. With regard to Gln, which is exclusively synthesized in astrocytes, its relatively high labelling from acetate supports the preferred [45], albeit not exclusive [30,32] astrocytic metabolism of acetate.

Most previous studies in which MSO was found to significantly affect generation of Glu from [13C] metabolic intermediates (glucose and/or acetate) have analyzed effects of direct application of MSO to in vitro preparations, at concentrations ranging from 1 to 10 mM [30–32]. Significant reduction of [13C] glucose flux in the brain in vivo was reported upon 6h after injection of 150 mg/kg MSO i.p. [24], which is a sub-acute dose reported to cause convulsion [46]. The here used 75 mg/kg i.p. dose of MSO administered for 165-210 min was comparatively low, likely below the threshold required to produce a significant effect. It is intriguing, however, that the reduction of [13C]-enrichment of Gln and Glu from glucose at the 15 min time point by MSO found in control rats, was not observed in Pilo-treated rats. The mechanism by which Pilo abrogated the effect of MSO could be related to deregulation of glucose metabolism. Depending upon the experimental setting, Pilo-induced seizures in their initial phase are accompanied either by an increased [47–50] or decreased cerebral glucose uptake/consumption [51–53]. Whatever their direction, the changes in glucose metabolism inflicted by Pilo-induced seizures may interfere with the effects of MSO. It is likely that in the MSO+Pilo group, the effect of MSO is additionally masked by Pilo-evoked release of a large pool of unlabeled Glu, indeed, a small tendency towards decrease of a [13C] labelled Glu pool is noted at 15' post-Pilo (Fig. 1. A.)

The observation that MSO added at a low, non-convulsive dose did not significantly affect the [13C]-enrichment of Gln or Glu in Li-Pilo-stimulated brain slices substantiated investigation of GGC-bypassing effects of MSO on Glu release and uptake. The key observation made was that MSO markedly reduced the release of newly loaded [3H]D-Asp from ex vivo brain slices subjected to the isotonic depolarization stimulus (75 mM K+). [3H]D-Asp release has been observed to mimic fairly well depolarization evoked release of the synaptic vesicular pool of Glu in brain slices [54] and cultured neurons [55]. Earlier, this paradigm proved useful in explaining variable responses of glutamatergic transmission in different models of hepatic encephalopathy [56]. The present results suggest that in the Li-Pilo-treated rats in situ, MSO attenuated the glutamatergic aspect of the initial seizures by directly inhibiting Glu release, albeit interactive interference of MSO and Pilo with the with the metabolism of Glu precursors to Glu described in the previous paragraph cannot be excluded. Since induction and propagation of seizures by Pilo is subject to a complex mechanism encompassing a yet not fully resolved interplay of cholinergic and glutamatergic stimulation [57,58], it is clear that the reduction of the release, noted in brain slices obtained from MSO-treated rats in response to a single depolarizing stimulus, can only be considered as a rough approximation of its seizure-attenuating effect of Pilo in situ. Of note, basal, unstimulated [3H]D-Asp release from the slices was not affected by MSO exposure (Fig. 3.), a finding contrasting with stimulation of Glu release observed in different experimental settings at pro-convulsive MSO doses [33,35]. The above discrepancy underscores the dose-dependent duality of the effects of MSO.

VGLUT1 is the principal vesicular Glu transporter responsible for loading synaptic vesicles with glutamate, and as such a specific marker for the glutamatergic networks [36]. Notably, VGLUT1 is present in all intrinsic glutamatergic types of neurons of hippocampus [59], the structure involved in generation of seizures by pilocarpine and other chemical stimulants [60]. The decrease of VGLUT1 protein content by MSO may thus underlie the attenuation of [3H]D-Asp release observed in brain slices obtained from MSO-treated rats. The mechanism underlying MSO-induced VGLUT1 protein loss remains to be re-
solved. MSO may affect VGLUT1 protein synthesis or degradation directly, but alternatively or in addition, the response may be secondary to MSO-induced loss of a pertinent pool of synaptic Glu and/or Gln.

Increase of VGLUT1 protein has been recorded in autopsied hippocampi of human patients suffering from chronic TLE [61] and of rats in which pilocarpine treatment led to the development of SRS [62]. Whether the MSO-induced decrease of VGLUT1 contributes to the glutamergic aspect of pilocarpine-induced initial seizures remains to be unequivocally proven: the caveats to this interpretation are the same as those outlined above with regard to the [3H]-Asp release study. If this interpretation is correct, and the decrease is sustained throughout development of TLE to its full-blown stage, MSO would be a valuable addition to the hotly debated list of antiepileptic drugs with antiepileptogenic activity [63]. The fact that MSO is relatively much less neurotoxic in primates than in rodents [9] substantiates further search into its antiepileptogenic potential.

It cannot be excluded that modulation by MSO of glutamatergic transmission involves other Gln synthesis-bypassing mechanisms as well. MSO inhibits not only GS, but also γ-glutamylcysteine synthetase, an enzyme diverting a significant portion of Glu towards glutathione synthesis [64]. MSO was also found to variably affect Gln fluxes in cultured astrocytes [65], and brain cortex slices [66]. However, the above mentioned findings were obtained in experimental conditions not easily translatable to those recorded in ex vivo slices in the present study.

In conclusion, notwithstanding a number of caveats to be resolved, the results of the present study may be best interpreted as indicating that MSO at a non-convulsive dose mitigates the initial Pilo-induced seizures by interfering with mechanism of Glu release. By contrast, the results do not support the view that the “canonical” glutamine synthetase-inhibiting activity of MSO plays an essential role in the attenuation of the seizures at this stage.

4. Materials and Methods

4.1. Juvenile rat Li⁺-pilocarpine TLE model

The procedure was essentially as described previously [1,67] with minor modifications. At postnatal day 23 (P23), male Sprague Dawley rats (the animal colony of the Mossakowski Medical Research Institute, Polish Academy of Sciences in Warsaw) were injected intraperitoneally (i.p.) with lithium carbonate (222 mg/kg; Sigma) dissolved in saline (pH equalized to 7.4). At P24, 18-20h after Li+ treatment, animals were injected i.p. with methyl-scopolamine (1 mg/kg; Sigma) and thirty minutes later with pilocarpine (Pilo (40 mg/kg; Sigma). From then on, animal’s behavior was continuously monitored. Rats were decapitated either 15’ (onset phase) or 60’ (final phase) after Pilo administration (see also paragraph 4.3).

4.2. Pretreatment with MSO

MSO (Sigma) was dissolved in saline and administered i.p. at 75 mg/kg. Rats that were used in experiments with Pilo received MSO 150 min before Pilo, thus 165 min or 210 min before decapitation. Rats that were used in experiments with Pilo received MSO 150 min before Pilo, thus 165 min (Fig. 1., 2. A-D) or 210 min (Fig. 1., 2. E-H, Fig. 4) before decapitation. Rats used for ex vivo experiments with brain slices received MSO 210 min before decapitation (Fig. 3.). Control rats that did not receive MSO were given equal volumes of saline at the same time.

4.3. Metabolic studies in vivo

The following procedures were based on previously published papers [27,68]. Rats divided into four groups (control, MSO, Pilo, MSO+Pilo) received a single i.p. dose of [U-13C]glucose (543 mg/kg) or [1,2-13C]acetate (504 mg/kg) (Cambridge Isotope Laboratories) dissolved in saline, either at the same time as Pilo (onset) or 45 minutes after the injection
of Pilo (final phase). All animals were decapitated after 15 minutes. Therefore the precursors were present in the body at the onset and in the final phase of Pilo action. Brain tissue was immediately dissected and frozen in liquid nitrogen. Frozen hippocampi and entorhinal cortex samples were homogenized in 2 mL of ice-cold 70% ethanol and then centrifuged for 20 min at 20,000 × g. Supernatant was collected, lyophilized, and used for amino acids analysis in GC-MS and HPLC; pellets were used for protein determination with the BCA assay (Thermo Fisher Scientific).

4.3.1. Metabolic mapping using gas chromatography coupled to mass spectrometry (GC-MS)

Lyophilized extracts from hippocampus and entorhinal cortex tissue were resuspended, acidified to pH 1-2 with HCl and subsequently evaporated to dryness using nitrogen. With the use of 96 % ethanol and benzene, the analytes were extracted, evaporated again to dryness and derivatized with 14 % DMF/ 86 % MTBSTFA [69]. Gas chromatography (GC, Agilent Technologies 7820A chromatograph, J&W GC column HP-5MS, parts no. 19091S-433) coupled to mass spectrometry (MS, Agilent Technologies, 5977E) was used to separate and analyze the samples. With the use of unlabeled standards, metabolites of interest were corrected to their $^{13}$C natural abundance in order to assess their isotopic enrichment. Calculations were performed according to [70]. Data integration and enrichment determination was performed with the software MassHunter Quantitative Analysis software v.6.0.3881 (Agilent Technologies). Data is presented as labelling (%) of M+X, where M is the mass of the unlabelled molecule and X is the number of labelled C-atoms in a given metabolite.

4.3.2. Quantitative determination of intracellular amino acids by HPLC

Tissue extracts, previously resuspended in water, were separated by reverse-phase high performance liquid chromatography (HPLC) using an Agilent ZORBAX Eclipse plus C18 column (4.6 × 150 mm, particle size 3.5 μm; 959,963–902, Agilent Technologies, Santa Clara, CA, USA) in an Agilent 1260 Infinity system coupled to a 1260 Infinity fluorescence detector (Agilent Technologies) as described previously [71]. Briefly, samples were derivatized with o-phthaldialdehyde and separation was performed with a mobile phase gradient consisting of a mixture of buffer A (10 mM Na$_2$HPO$_4$ : 10 mM Na$_2$B$_4$O$_7$ pH 6.9; 5 mM NaN$_3$) and buffer B (acetonitrile 45% : methanol 45% : water 10%, v:v:v). Amino acids quantification was performed using standards containing a mixture of the amino acids of interest on increasing concentrations. The acquired data was normalized to the protein concentration in the dry tissue samples. Effects of MSO on the Gln content could not be accurately assessed because the position of the MSO peak which was in much excess over Gln largely overlapped with the position of the latter.

4.4. Metabolic studies ex vivo on acute brain slices

Rats anesthetized with isoflurane (Baxter) were decapitated, the brain was immediately removed, and cortices were cut into 350 μm thick slices, using McIlwain tissue chopper. The slices were pre-incubated for 30 minutes in the Krebs buffer (37°C, aerated with 95 % O2 and 5%CO2, pH 7.4 ), composed of [mM]: 118 NaCl, 25 NaHCO$_3$, 4.7 KCl, 1.2 KH$_2$PO$_4$, 2.5 CaCl$_2$, 1.2 MgSO$_4$, 10 glucose. After preincubation, slices were used either for uptake or efflux measurement protocols, employing the radioactive [$^3$H]D-Asp as the non-metabolised analogue of glutamate.

4.4.1. [$^3$H]D-Asp efflux assay

The [$^3$H]D-Asp efflux was assayed based on the method previously described [72], with modifications. [$^3$H]D-Asp efflux was measured after 15 minutes incubation in Krebs buffer containing 1.4 μCi/mL [$^3$H]D-Asp (Perkin-Elmer) and unlabeled D-Asp (100 μmol/L). The slices were moved to a chamber perfusion system (Brandel) and rinsed with Krebs buffer at 0.5 mL/min rate. The initial fraction was collected for 20 min to establish baseline efflux. Perfusate samples were then collected for 20 min, at 1 min intervals. At
the time period indicated in \textbf{Figure . A.} (fractions 5 and 6), a depolarizing pulse was introduced by raising KCl concentration in the Krebs buffer to 75 mM, with simultaneous reduction of NaCl to 47.7 mM). Radioactivity contained in the preparation and released from brain slices were measured by a Wallac 1409 Liquid Scintillation Counter (Perkin-Elmer).

4.4.2. [\textsuperscript{3}H]-Asp uptake assay

The [\textsuperscript{3}H]-Asp uptake was assayed as previously described [73]. Briefly, the uptake was initiated by adding [\textsuperscript{3}H]-Asp, 0.1 μCi/1 mL (Perkin-Elmer), to varying extracellular concentrations of unlabelled D-Asp (50–2000 μM). The incubation with the radioisotope was continued for 3 min and was terminated by rapid vacuum filtration through nitrocellulose filter disks (Millipore), followed by flushing four times with 2 mL of ice-cold Krebs buffer. The slices were weighed, immersed in 4 mL of InstaGel scintillation fluid (Perkin-Elmer), and the radioactivity of slices on filter disks was measured in the Wallac 1409 Liquid Scintillation Counter (Perkin-Elmer).

4.5. \textit{VGluT1} analysis

4.5.1. RT-qPCR

Total RNA was isolated from hippocampus using TRI Reagent (Sigma). Extracted RNA was reversely transcribed using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The mRNA expression was determined by Taqman Gene Expression Assays (Applied Biosystems), using 1 μl of cDNA in a reaction of 10 μl. The assay IDs were Rn01462431_m1 for rat VGLUT1 and Rn00667869_m1 for β-actin. The fold change in the gene expression was determined by the 2\(^{-ΔΔCt}\) method [74].

4.5.2. Western Blotting

After decapitation, immediately removed rat hippocampus was isolated on ice and snap-frozen in liquid nitrogen. Frozen tissue samples were homogenized in buffer and centrifuged as described by Popek et al. [75]. Protein concentrations were performed using a BCA Protein Assay (Thermo Fisher Scientific). The content of VGluT1 protein was assessed by Western Blotting as previously described [75,76]. Membranes were incubated overnight at 4\(^\circ\) C with anti-VgluT1 antibody (cat. no. EPR22269, 1:1000) (Abcam), washed, incubated with HRP-conjugated IgG (cat. no. 269A-1 1:5000) (Sigma) and developed using Chemiluminescent Super Signal West Pico Substrate (Pierce). After stripping, the membranes were incubated with HRP-conjugated anti-GAPDH antibody for 1 h (cat. no. HRP-60004, 1:10000) (Proteintech), which was used as a loading control, and developed as described above. Data were expressed as percentage change in fluorescent band intensity of VGLUT1 antibody divided by GAPDH.

4.6. Data evaluation

All statistical analysis were performed with Prism 7.0 (GraphPad) software. T-tests were used for comparisons of two groups and one-way ANOVA for more than two groups. Multiple comparisons were followed by Holm-Šidák’s (multiple t-tests) or Tukey’s (ANOVA) post hoc tests. The significance level was set at \(p < 0.05\).


\textbf{Funding:} This work was supported by the National Science Centre (NCN) of Poland (2016/23/B/NZ4/03678) and by ESF (POWR.03.02.00-00-I028/17-00).

\textbf{Institutional Review Board Statement:} Animal experiments were conducted according to the guidelines of the Declaration of Helsinki and the national guidelines on animal experimentation,
and were approved by the local ethical committee in Warsaw (consent no. 405/2017, 21.11.2017) in accordance with EC Directive 2010/63/EU.

**Informed Consent Statement**: Not applicable.

**Data Availability Statement**: Data available on request.

**Acknowledgments**: The authors would like to thank Dr Jolanta Dyniewicz and Katarzyna Kosinski from the Department of Neuropeptides of MMRI PAS for their invaluable help with samples lyophilisation.

**Conflicts of Interest**: The authors declare no conflict of interest.

5. References


29. Andersen, J. V.; Christensen, S.K.; Westi, E.W.; Diaz-delCastillo, M.; Tanila, H.; Schousboe, A.; Aldana, B.I.; Waagepetersen, H.S. Deficient astrocyte metabolism impairs glutamine synthesis and neurotransmitter homeostasis in a mouse model of...


47. Motte, J.; Fernandes, M.J.D.S.; Baram, T.Z.; Nehlig, A. Spatial and temporal evolution of neuronal activation, stress and injury.


